arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOREGENX, INC.

BRGX
— Price unavailable
Technology ·Services-Computer Programming, Data Processing, Etc. ·USServices-Computer Programming, Data Processing, Etc.
6 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

BIOREGENX, INC. shows mixed fundamentals. However, watch Operating Margin (%) and Profit Margin (%) which show concerning trends. Consider comparing against peers in the Technology sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth -20.8% ↘
Op. Margin -67.1%
ROIC 29.3% ↘
FCF / Share $0.00 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.26
info Valuation on last close.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.85M
↓ -20.8% —
Net Income Profit after all expenses
$-1.54M
↑ +93.3% —
Operating Margin Operating profit as % of sales
-67.1%
↑ +86.4% 4th
FCF / Share Free cash flow per share
$0.00
↑ +105.7% —
Long-Term Debt Long-term obligations
$1.19M
↑ +4.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
12
Returns ↓
94
Financial Health ↑
69
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 19 quarters